Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study. - Wikidata - awgldk - TriplyDB

Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study.

Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study.

http://www.wikidata.org/entity/Q37235902

about

Soluble Receptor for Advanced Glycation End Product: A Biomarker for Acute Coronary Syndrome Low levels of serum soluble receptors for advanced glycation end products, biomarkers for disease state: myth or reality Interactions between smoking, pulmonary surfactant protein B, and atherosclerosis in the general population: the Dallas Heart Study Elevation of high-mobility group box 1 after clinical autologous islet transplantation and its inverse correlation with outcomes Alternatively spliced RAGEv1 inhibits tumorigenesis through suppression of JNK signaling Effect of dietary advanced glycation end products on mouse liver Association of serum soluble receptor for advanced glycation end-products with subclinical cerebrovascular disease: the Northern Manhattan Study (NOMAS)Association of plasma levels of soluble receptor for advanced glycation end products and risk of kidney disease: the Atherosclerosis Risk in Communities study Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial Serum levels of soluble receptor for advanced glycation end-products and metabolic syndrome: the Northern Manhattan Study Serum level of endogenous secretory receptor for advanced glycation end products and other factors in type 2 diabetic patients with mild cognitive impairment Race-specific associations of myeloperoxidase with atherosclerosis in a population-based sample: the Dallas Heart Study Genetics of Plasma Soluble Receptor for Advanced Glycation End-Products and Cardiovascular Outcomes in a Community-based Population: Results from the Atherosclerosis Risk in Communities Study Cilostazol attenuates the severity of peripheral arterial occlusive disease in patients with type 2 diabetes: the role of plasma soluble receptor for advanced glycation end-products.Soluble receptor for advanced glycation end products and the risk for incident heart failure: The Atherosclerosis Risk in Communities Study.Vasoregression: A Shared Vascular Pathology Underlying Macrovascular And Microvascular Pathologies?sRAGE and risk of diabetes, cardiovascular disease, and death Serum soluble RAGE levels and carotid atherosclerosis: the Northern Manhattan Study (NOMAS).IL-1β, RAGE and FABP4: targeting the dynamic trio in metabolic inflammation and related pathologies.Advanced glycation end-products, a pathophysiological pathway in the cardiorenal syndrome RAGE biology, atherosclerosis and diabetes.Beneficial and detrimental effects of glycemic control on cardiovascular disease in type 2 diabetes.Role of Advanced Glycation End Products and Its Receptors in the Pathogenesis of Cigarette Smoke-Induced Cardiovascular Disease.Circulating soluble receptor for advanced glycation end product: Cross-sectional associations with cardiac markers and subclinical vascular disease in older men with and without diabetes.Statins stimulate the production of a soluble form of the receptor for advanced glycation end products.AGEs/sRAGE, a novel risk factor in the pathogenesis of end-stage renal disease.Cross-sectional Analysis of AGE-CML, sRAGE, and esRAGE with Diabetes and Cardiometabolic Risk Factors in a Community-Based Cohort.Lycopene supplementation reduces TNF-α via RAGE in the kidney of obese rats.Response to comments on: Selvin et al. sRAGE and risk of diabetes, cardiovascular disease, and death. Diabetes 2013;62:2116-2121.Association between arterial elasticity indices and coronary artery calcium in a healthy multi-ethnic cohort.RAGE gene polymorphism in heart failure patients with and without angiographic evidence of significant coronary atherosclerosis.The AGE-RAGE axis in an Arab population: The United Arab Emirates Healthy Futures (UAEHFS) pilot study.Soluble receptor of advanced glycation end products levels are related to ischaemic aetiology and extent of coronary disease in chronic heart failure patients, independent of advanced glycation end products levels: New Roles for Soluble RAGE.Plasmatic Soluble Receptor for Advanced Glycation End Products as a New Oxidative Stress Biomarker in Patients with Prosthetic-Joint-Associated Infections?Racial differences in circulating levels of the soluble receptor for advanced glycation endproducts in middle-aged and older adults.Relationships between vitreous levels of soluble receptor for advanced glycation end products (sRAGE) and renal function in patients with diabetic retinopathy.The Number of GT(n) Repeats in the Hemeoxygenase-1 Gene Promoter is Increased in Pediatric Heart Failure but is Unrelated to Renal, Antioxidant and Anti-inflammatory Markers.

P2860

Q26780488-2174F09A-1072-4AF0-A233-25950ECE7425 Q26859793-4FC2EFC2-923E-45B3-9256-325C543AE05A Q28244928-EC1A75EE-0FA4-44A0-B4E9-E6F8325E691A Q33894332-BE97FD5F-30E7-4B55-AC77-7C1246D1C8C2 Q34056610-01E00BA6-86F5-45BB-9453-C74DFCFAAA2E Q34230496-15F4F827-C442-479C-A7A9-56C256AB6EB1 Q34949171-F404FC6D-9913-4AC0-81FD-70A4696E3C9C Q35152739-8DAB80E6-4DCB-4E07-B72B-4F256C7381B6 Q35180065-6C3C46D1-23DC-4C17-957C-6B9DD4F8CA4C Q35234754-472B6224-9802-4C7B-9AB4-F1AF2106566B Q35563671-6529FF18-9906-4DCB-83DC-98CDA4475580 Q35581112-BE44201F-87DD-4240-A0FC-3FDD7CF86092 Q35666321-974D3EBF-33EF-405A-9459-F75B01E0B887 Q35882416-2D8799D9-75A0-4424-B929-7C54F684D49F Q36263332-0A3183C8-9FCC-43B2-9013-1452AC9A0646 Q36384149-C05172C4-0AE9-47FC-8C59-F7324E70DF20 Q36867450-D96F0761-C688-4B42-BB2D-76D74B1CB9E8 Q36935766-3074A3C0-1ECE-4CA1-B928-FF3B340F9FA4 Q37305013-A46F54CB-DC36-43B2-ACD5-20DFCC3CD004 Q37831838-9D538E8C-0E32-4C90-85D5-AACB205436DB Q37860348-684967B3-B6DE-4F85-AE32-A0B6B26413F5 Q38073629-CE0E0917-157F-48EF-A9F0-312655D1F755 Q38523267-A7C7260E-E6D2-4030-A218-0E0504D7A29B Q38651423-A4D9654D-9E7F-459A-BD31-B2CE278480D0 Q39106836-B1BD831C-CFA1-4D54-BD57-B57788980B27 Q39313922-ADAE27DD-CF9D-4229-A549-1E8EC950502D Q40298930-F74D01C5-856D-4F20-AC9A-65A352752742 Q42535779-D84FD7A0-13A4-4635-9411-9D53FC484AEA Q42970469-82A8E4C0-3DA5-4361-A5DA-3303811586A4 Q44753291-E7014EA1-00F8-4F09-862F-79EB9AA62ECD Q46632155-D45CE555-774B-4F85-9BC8-D75440F5C7E0 Q47162406-1BF9DB7C-944E-4E93-AF88-1D76BC6F7EB5 Q48100352-4DB5799A-A11E-437A-9C1D-AE1C676D7A77 Q48130190-3C0E6EC9-1C79-494E-A908-9C39DEBCC408 Q51061874-6F1F5D02-185B-4F46-9B90-86BA8869D60C Q51335095-A042F3B4-D43A-4A02-BBF6-BDCACBC21387 Q53804883-355482AE-A23F-4F44-96F3-65F17F5E0732

P2860

Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study.

http://www.wikidata.org/entity/Q37235902

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 14 April 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Association between circulatin ...... s from the Dallas Heart Study.

@en

Association between circulatin ...... s from the Dallas Heart Study.

@nl

type

label

Association between circulatin ...... s from the Dallas Heart Study.

@en

Association between circulatin ...... s from the Dallas Heart Study.

@nl

prefLabel

Association between circulatin ...... s from the Dallas Heart Study.

@en

Association between circulatin ...... s from the Dallas Heart Study.

@nl

P1433

Q37235902-7A9FB042-77E1-4926-B937-EF68A0E23FB1

P1476

Q37235902-BFC9C85F-E726-4EBD-9F13-677B4FD09E91

P2093

Q37235902-32C35A43-0D89-44A7-AE4B-FA87059AA0FA

Q37235902-642AB59C-739B-4EEA-B922-84737B528921

Q37235902-808908FB-94AB-4C72-AB75-47F7B4A1F08A

Q37235902-85FA65B8-3A2A-4570-B672-83E5785E3E84

Q37235902-9E149E66-FB82-4202-8DDD-B915073F55D2

Q37235902-9FE67ED0-00D9-4569-8516-41E27B809F34

Q37235902-F628B229-E4FA-4CE5-B0F8-EEDE0576AEC1

P2860

Q37235902-0CE58501-89F0-4F60-BF86-78D7DAE409E9

Q37235902-0D77B1CF-BA04-4164-B8C1-2E1599A97D81

Q37235902-0E937443-BE33-401E-B8E7-C3E72B6B21DC

Q37235902-2028828E-C539-4EAC-BE9D-E2036E47716E

Q37235902-3C1F8D92-89C5-4779-ACFB-523A9C592028

Q37235902-4554CFEC-E908-4B72-B309-63C7688523EB

Q37235902-5D947859-CDDC-47E3-AB67-CE95BA7A3873

Q37235902-6167861A-F697-42B3-A4DF-D4CB4C740009

Q37235902-79A25C05-A801-476E-B22F-63F169FEE6C9

Q37235902-85A8D6E1-5025-44CE-8622-8D27293D1BCE

P304

Q37235902-10F224A8-79B9-47F5-8955-3BB6718F8C0A

P31

Q37235902-4EC2975C-4583-46B3-A20C-56DEF5CDB837

P356

Q37235902-7C027047-CC5B-4710-A78E-88EE0D4B7E28

P407

Q37235902-8F49107A-71B4-407E-9036-DAF18AE285D4

P433

Q37235902-9B5596BF-3BF5-4B9B-A8D3-439566C43D55

P478

Q37235902-94B13967-319F-499E-8B85-7C5D1D3F62B9

P50

Q37235902-C6C9F318-F800-4085-B4FE-578E994AEC84

P577

Q37235902-0CBA0355-8D9B-42D1-854C-22286CC537B4

P5875

Q37235902-C79AD1D4-555C-4535-9AF5-1B0EBEFEF747

P698

Q37235902-E31E3310-74DB-4CD2-BEBA-FB0C5C8BDCB9

P921

Q37235902-48F0659F-C64A-4F44-BAF7-E9E4C49BA0F6

P932

Q37235902-083E6539-2EEB-48DE-9B39-DEECA05761B1

P356

P1433

P1476

Association between circulatin ...... ns from the Dallas Heart Study

@en

P2093

Amit Khera

http://www.w3.org/2001/XMLSchema#string

Anand Rohatgi

http://www.w3.org/2001/XMLSchema#string

Colby R Ayers

http://www.w3.org/2001/XMLSchema#string

Darren K McGuire

http://www.w3.org/2001/XMLSchema#string

David A Morrow

http://www.w3.org/2001/XMLSchema#string

James A de Lemos

http://www.w3.org/2001/XMLSchema#string

Jason B Lindsey

http://www.w3.org/2001/XMLSchema#string

P2860

Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men.

Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues.

Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications.

Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury.

Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts.

RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice.

Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis.

African Americans and Caucasians have a similar prevalence of coronary calcium in the Dallas Heart Study.

RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes.

Expression of a novel secreted splice variant of the receptor for advanced glycation end products (RAGE) in human brain astrocytes and peripheral blood mononuclear cells.

P304

1218-1220

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC09-0053

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

Francesco Cipollone

P577

2009-04-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24278113

http://www.w3.org/2001/XMLSchema#string

P698

19366975

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis

P932

2699719

http://www.w3.org/2001/XMLSchema#string